Topical prophylaxis for HIV prevention in women: Becoming a reality

Current HIV/AIDS Reports

Volumn 8, Issue 2, 2011, Pages 104-113

  Verma, Natasha A ^a   Lee, Anna C ^a   Herold, Betsy C ^a   Keller, Marla J ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Adherence; Antiretroviral drugs; Biomarkers; Dapivirine; Genital tract; Herpes simplex virus; Human immunodeficiency virus; Intravaginal ring; Maraviroc; Pharmacodynamics; Pharmacokinetics; Pre exposure prophylaxis; Tenofovir; Topical microbicides

Indexed keywords

ANTIRETROVIRUS AGENT; BMS 599793; DAPIVIRINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; IQP 0528; MICROBICIDE; MIV 150; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; RC 101; TENOFOVIR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SUSTAINED RELEASE FORMULATION; UNSPECIFIED SIDE EFFECT; VAGINA RING;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; DELAYED-ACTION PREPARATIONS; FEMALE; HIV INFECTIONS; HUMANS;

EID: 79957530096     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-011-0075-7     Document Type: Article

References (50)

1. Joint United Nations Programme on HIV/AIDS: UNAIDS Report on the Global AIDS Epidemic 2010. In Edition Available at http://www.unaids.org/documents/ 20101123-GlobalReport-em.pdf. Accessed December 2010.
2. Q Abdool Karim SS Abdool Karim JA Frohlich, et al. 2010 Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 329 1168 1174 20643915 10.1126/science.1193748 1:CAS:528:DC%2BC3cXhtV2hsr%2FI This article provides the findings of the CAPRISA 004 study, which established proof of concept that a vaginal microbicide containing an antiretroviral can protect women from HIV. In this study, 1% tenofovir gel used before and after sex reduced HIV acquisition by 39%
3. RH Gray G Kigozi D Serwadda, et al. 2007 Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial Lancet 369 657 666 17321311 10.1016/S0140-6736(07)60313-4
4. RA Crosby RJ DiClemente GM Wingood, et al. 2008 Sexual agency versus relational factors: a study of condom use antecedents among high-risk young African American women Sex Health 5 41 47 18361853 10.1071/SH07046 (Pubitemid 351301117)
5. RM Grant JR Lama PL Anderson, et al. 2010 Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 2587 2599 21091279 10.1056/NEJMoa1011205 1:CAS:528:DC%2BC3MXit1ansg%3D%3D
6. Kashuba A, Abdool Karim SS, Kraft E, et al.: Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial? [abstract TUSS0503]. Presented at the XVIII International AIDS Conference, Vienna, Austria; July 18-23, 2010.
7. S Patel E Hazrati N Cheshenko, et al. 2007 Seminal plasma reduces the effectiveness of topical polyanionic microbicides J Infect Dis 196 1394 1402 17922405 10.1086/522606 1:CAS:528:DC%2BD2sXhtlOmtbfM (Pubitemid 351412013)
8. L Van Damme G Ramjee M Alary, et al. 2002 Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial Lancet 360 971 977 12383665 10.1016/S0140-6736(02) 11079-8 (Pubitemid 35284107)
9. L Van Damme R Govinden FM Mirembe, et al. 2008 Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission N Engl J Med 359 463 472 18669425 10.1056/NEJMoa0707957
10. PM Mesquita N Cheshenko SS Wilson, et al. 2009 Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety J Infect Dis 200 599 608 19586414 10.1086/600867 1:CAS:528: DC%2BD1MXhtV2gs7nK
11. SS Wilson N Cheshenko E Fakioglu, et al. 2009 Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety Antivir Ther 14 1113 1124 20032541 10.3851/IMP1463 1:CAS:528:DC%2BC3cXitVyqurg%3D
12. LC Rohan BJ Moncla RP Kunjara Na Ayudhya, et al. 2010 In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide PLoS ONE 5 e9310 20174579 10.1371/journal.pone.0009310
13. UM Parikh C Dobard S Sharma, et al. 2009 Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine J Virol 83 10358 10365 19656878 10.1128/JVI.01073-09 1:CAS:528:DC%2BD1MXhtlClsbjE This study used a repeated low-dose challenge model of simian-human immunodeficiency infection and showed that preexposure vaginal application of gel with 1% tenofovir alone or in combination with 5% emtricitabine fully protected macaques. This study provides a rationale for including antiretroviral combinations in HIV prevention trials
14. EE Freeman HA Weiss JR Glynn, et al. 2006 Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies AIDS 20 73 83 16327322 10.1097/01.aids.0000198081.09337.a7 (Pubitemid 41818117)
15. P Fletcher S Harman H Azijn, et al. 2009 Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor Antimicrob Agents Chemother 53 487 495 19029331 10.1128/AAC.01156-08 1:CAS:528:DC%2BD1MXhslentb4%3D
16. AM Nel P Coplan JH van de Wijgert, et al. 2009 Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women AIDS 23 1531 1538 19550287 10.1097/QAD.0b013e32832c413d 1:CAS:528:DC%2BD1MXovVSgs7k%3D
17. AM Nel SC Smythe S Habibi, et al. 2010 Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel J Acquir Immune Defic Syndr 55 161 169 20574411 10.1097/QAI.0b013e3181e3293a 1:CAS:528:DC%2BC3cXhtFyqtr7F
18. J Romano B Variano P Coplan, et al. 2009 Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring AIDS Res Hum Retroviruses 25 483 488 19388819 10.1089/aid.2008.0184 1:CAS:528: DC%2BD1MXlvF2ku7k%3D
19. A Nel S Smythe K Young, et al. 2009 Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women J Acquir Immune Defic Syndr 51 416 423 19623693 10.1097/QAI. 0b013e3181acb536 1:CAS:528:DC%2BD1MXotlehuro%3D
20. AR Geonnotti DF Katz 2010 Compartmental transport model of microbicide delivery by an intravaginal ring J Pharm Sci 99 3514 3521 20222027 10.1002/jps.22120 1:CAS:528:DC%2BC3cXnvFGrsr4%3D
21. G Borkow J Barnard TM Nguyen, et al. 1997 Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase J Virol 71 3023 3030 9060662 1:CAS:528:DyaK2sXhvVCqs7k%3D (Pubitemid 27119946)
22. JL Schwartz G Kovalevsky JJ Lai, et al. 2008 A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor Sex Transm Dis 35 414 419 18362865 10.1097/OLQ. 0b013e318162c4d8 1:CAS:528:DC%2BD1cXjs1Kitbo%3D (Pubitemid 351440786)
23. RW Buckheit Jr TL Hartman KM Watson, et al. 2008 Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2 Antimicrob Agents Chemother 52 225 236 17967909 10.1128/AAC.00972-07 1:CAS:528:DC%2BD1cXkslehuw%3D%3D
24. JA Fernandez-Romero M Thorn SG Turville, et al. 2007 Carrageenan/MIV-150 (PC-815), a combination microbicide Sex Transm Dis 34 9 14 16924181 10.1097/01.olq.0000223287.46097.4b 1:CAS:528:DC%2BD2sXjtVGh (Pubitemid 46041501)
25. SG Turville M Aravantinou T Miller, et al. 2008 Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity PLoS ONE 3 e3162 18776937 10.1371/journal.pone.0003162
26. JB Dumond KB Patterson AL Pecha, et al. 2009 Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women J Acquir Immune Defic Syndr 51 546 553 19546811 10.1097/QAI.0b013e3181ae69c5
27. RS Veazey TJ Ketas J Dufour, et al. 2010 Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor J Infect Dis 202 739 744 20629537 10.1086/655661 1:CAS:528:DC%2BC3cXhtFKjsr%2FF
28. Q Hu N Mahmood RJ Shattock 2007 High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization Virology 368 145 154 17658575 10.1016/j.virol.2007.06.029 1:CAS:528:DC%2BD2sXht1ahtb%2FM (Pubitemid 47599570)
29. V Buffa D Stieh N Mamhood, et al. 2009 Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models J Gen Virol 90 234 243 19088294 10.1099/vir.0.004358-0 1:CAS:528:DC%2BD1MXlsV2iuw%3D%3D
30. CC Tsai P Emau Y Jiang, et al. 2004 Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models AIDS Res Hum Retroviruses 20 11 18 15000694 10.1089/088922204322749459 1:CAS:528:DC%2BD2cXpsFShtw%3D%3D (Pubitemid 38147172)
31. BR O'Keefe F Vojdani V Buffa, et al. 2009 Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component Proc Natl Acad Sci USA 106 6099 6104 19332801 10.1073/pnas.0901506106
32. O Hartley H Gaertner J Wilken, et al. 2004 Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors Proc Natl Acad Sci USA 101 16460 16465 15545608 10.1073/pnas.0404802101 1:CAS:528:DC%2BD2cXhtVOisbrE (Pubitemid 39557735)
33. MM Lederman RS Veazey R Offord, et al. 2004 Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5 Science 306 485 487 15486300 10.1126/science.1099288 1:CAS:528:DC%2BD2cXotlCkt78%3D (Pubitemid 39372448)
34. F Cerini A Landay C Gichinga, et al. 2008 Chemokine analogues show suitable stability for development as microbicides J Acquir Immune Defic Syndr 49 472 476 18989226 10.1097/QAI.0b013e31818c953f 1:CAS:528: DC%2BD1MXkt1GrsA%3D%3D
35. RS Veazey B Ling LC Green, et al. 2009 Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge J Infect Dis 199 1525 1527 19331577 10.1086/598685 1:CAS:528:DC%2BD1MXmtV2it7Y%3D
36. LC Rohan AB Sassi 2009 Vaginal drug delivery systems for HIV prevention AAPS J 11 78 87 19194802 10.1208/s12248-009-9082-7 1:CAS:528:DC%2BD1MXhtVWru7fJ
37. E Hardy EM Hebling MH Sousa, et al. 2007 Delivery of microbicides to the vagina: difficulties reported with the use of three devices, adherence to use and preferences Contraception 76 126 131 17656182 10.1016/j.contraception.2007. 04.013 1:CAS:528:DC%2BD2sXotlWltbg%3D (Pubitemid 47082515)
38. KM Gupta SM Pearce AE Poursaid, et al. 2008 Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1 J Pharm Sci 97 4228 4239 18338805 10.1002/jps.21331 1:CAS:528:DC%2BD1cXht1Sgt7rF This article describes the novel use of polyether urethane in the design of intravaginal rings to provide sustained release of antiretroviral microbicides
39. TJ Johnson KM Gupta J Fabian, et al. 2010 Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir Eur J Pharm Sci 39 203 212 19958831 10.1016/j.ejps.2009.11.007 1:CAS:528:DC%2BC3cXhtlGitrw%3D
40. PJ Feldblum A Adeiga R Bakare, et al. 2008 SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria PLoS ONE 3 e1474 18213382 10.1371/journal.pone.0001474 (Pubitemid 351796318)
41. Keller MJ, Madan RP, Torres NM, et al. A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One 2011; 6:e16475.
42. MJ Keller E Guzman E Hazrati, et al. 2007 PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity AIDS 21 467 476 17301565 10.1097/QAD.0b013e328013d9b5 1:CAS:528:DC%2BD2sXhslCmsr8%3D
43. S McCormack G Ramjee A Kamali, et al. 2010 PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial Lancet 376 1329 1337 20851460 10.1016/S0140-6736(10)61086-0 1:CAS:528:DC%2BC3cXht12ks7nN
44. IM Poynten IY Millwood MO Falster, et al. 2009 The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies AIDS 23 1245 1254 19474652 10.1097/QAD.0b013e32832b4271 1:CAS:528: DC%2BD1MXnt1Olsrc%3D
45. CW Hendrix YJ Cao EJ Fuchs 2009 Topical microbicides to prevent HIV: clinical drug development challenges Annu Rev Pharmacol Toxicol 49 349 375 19006450 10.1146/annurev.pharmtox.48.113006.094906 1:CAS:528: DC%2BD1MXisV2jsbo%3D Fundamental information regarding virus and drug distribution over time in the genital tract is needed to design a safe and effective microbicide. This article thoroughly reviews a conceptual framework for obtaining the knowledge that is likely to inform the construction of a mechanistic pharmacokinetic/pharmacodynamic model to better inform rational microbicide development
46. MJ Keller PM Mesquita NM Torres, et al. 2010 Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials PLoS ONE 5 e8781 20107502 10.1371/journal.pone.0008781 This is the first study to evaluate the pharmacokinetics and pharmacodynamics of a candidate microbicide following sex and demonstrated that both differ significantly from results obtained in the absence of sex. This article provides an important rationale for the inclusion of postcoital sampling in future microbicide trials
47. MJ Keller B Zerhouni-Layachi N Cheshenko, et al. 2006 PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial J Infect Dis 193 27 35 16323128 10.1086/498533 1:CAS:528:DC%2BD28Xks12gsQ%3D%3D (Pubitemid 43032495)
48. World Health Organization and Joint United Nations Programme on HIV/AIDS: Next Steps with 1% Tenofovir Gel Meeting Report. Available at http://www.who.int/reproductivehealth/topics/rtis/WHO-UNAIDS-Next-steps- tenofovir-gel-Ex-report.pdf. Accessed December 2010.
49. BD Welch JN Francis JS Redman, et al. 2010 Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance J Virol 84 11235 11244 20719956 10.1128/JVI.01339-10 1:CAS:528:DC%2BC3cXhsVeisb7E
50. AM Cole DL Patton LC Rohan, et al. 2010 The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques PLoS ONE 5 e15111 21124745 10.1371/journal.pone.0015111 1:CAS:528:DC%2BC3cXhsFaqu7bI